Therapeutics Highlights from ILC 2018, the EASL annual congress
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Clinics and research in hepatology and gastroenterology - 42(2018), 4 vom: 07. Sept., Seite 294-295 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Poupon, Raoul [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.08.2019 Date Revised 09.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clinre.2018.06.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM287816028 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM287816028 | ||
| 003 | DE-627 | ||
| 005 | 20231225054902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clinre.2018.06.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0959.xml |
| 035 | |a (DE-627)NLM287816028 | ||
| 035 | |a (NLM)30143450 | ||
| 035 | |a (PII)S2210-7401(18)30112-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Poupon, Raoul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutics Highlights from ILC 2018, the EASL annual congress |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2019 | ||
| 500 | |a Date Revised 09.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a CCR5 Receptor Antagonists |2 NLM | |
| 650 | 7 | |a FGF19 protein, human |2 NLM | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Pyridazines |2 NLM | |
| 650 | 7 | |a Sulfoxides |2 NLM | |
| 650 | 7 | |a cenicriviroc |2 NLM | |
| 650 | 7 | |a 15C116UA4Y |2 NLM | |
| 650 | 7 | |a Budesonide |2 NLM | |
| 650 | 7 | |a 51333-22-3 |2 NLM | |
| 650 | 7 | |a Uracil |2 NLM | |
| 650 | 7 | |a 56HH86ZVCT |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factors |2 NLM | |
| 650 | 7 | |a 62031-54-3 |2 NLM | |
| 650 | 7 | |a Ursodeoxycholic Acid |2 NLM | |
| 650 | 7 | |a 724L30Y2QR |2 NLM | |
| 650 | 7 | |a vedolizumab |2 NLM | |
| 650 | 7 | |a 9RV78Q2002 |2 NLM | |
| 650 | 7 | |a resmetirom |2 NLM | |
| 650 | 7 | |a RE0V0T1ES0 |2 NLM | |
| 650 | 7 | |a Bezafibrate |2 NLM | |
| 650 | 7 | |a Y9449Q51XH |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Clinics and research in hepatology and gastroenterology |d 2011 |g 42(2018), 4 vom: 07. Sept., Seite 294-295 |w (DE-627)NLM201280868 |x 2210-741X |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2018 |g number:4 |g day:07 |g month:09 |g pages:294-295 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clinre.2018.06.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2018 |e 4 |b 07 |c 09 |h 294-295 | ||